Jerusalem, 15 January, 2026 (TPS-IL) — Tel Aviv-based AI biotech firm Immunai has signed an agreement with U.S. pharmaceutical giant Bristol Myers Squibb to advance clinical development using its AI operating system, AMICA-OS. The platform analyzes high-dimensional immune data from clinical trials to generate insights into patient immune responses, supporting biomarker discovery, patient stratification, and therapy optimization.
“Through our work with Bristol Myers Squibb, we will translate complex immune data into actionable insights that can help advance better therapies,” said Immunai CEO Noam Solomon.
Related Topics
